SCHEMBL27493

SCHEMBL27493

c1ccc2c(c1)CCCCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
ITGB2 P05107 1/20 0.50
ICAM1 P05362 1/20 0.50
ITGAL P20701 1/20 0.50
LMNA P02545 2/20 0.44
CRHBP P24387 2/20 0.44
CRHR2 Q13324 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HTT P42858 1/20 0.44
OXTR P30559 1/20 0.42
CTNNB1 P35222 3/20 0.41
WNT3A P56704 3/20 0.41
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
BRD4 O60885 1/20 0.38
PRKCI P41743 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16340888 1.00 TSHR (0.52) TSHRITGB2ICAM1ITGALLMNA
SCHEMBL7066039 0.98 TSHR (0.50) TSHRITGB2ICAM1ITGALLMNA
SCHEMBL7064352 0.98 TSHR (0.50) TSHRITGB2ICAM1ITGALLMNA
SCHEMBL28007596 0.93 ITGB2 (0.52) TSHRITGB2ICAM1ITGALLMNA
SCHEMBL29356442 0.93 ITGB2 (0.52) TSHRITGB2ICAM1ITGALLMNA
Fluoride SCHEMBL28202465 0.93 ITGB2 (0.52) TSHRITGB2ICAM1ITGALLMNA
SCHEMBL8447 0.93 ITGB2 (0.52) TSHRITGB2ICAM1ITGALLMNA
SCHEMBL5313090 0.93 ITGB2 (0.52) TSHRITGB2ICAM1ITGALLMNA
Ammonia Solution, Strong SCHEMBL2078097 0.91 ITGB2 (0.50) TSHRITGB2ICAM1ITGALLMNA
Water SCHEMBL5189676 0.91 ITGB2 (0.50) TSHRITGB2ICAM1ITGALLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630404-A1 UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS ANGELINI PHARMA S.P.A. (IT) 2025-10-15 EP claimed
EP-4630406-A1 AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS ANGELINI PHARMA S.P.A. (IT) 2025-10-15 EP claimed
CN-119241528-A Benzo [ b ] oxepanes and uses thereof 浙江大学金华研究院 2025-01-03 CN claimed
WO-2024121048-A1 UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS ANGELINI PHARMA S.P.A. (IT) 2024-06-13 WO claimed
WO-2024121046-A1 AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS ANGELINI PHARMA S.P.A. (IT) 2024-06-13 WO claimed
CN-110770211-B Alpha, beta unsaturated amide compound 协和麒麟株式会社 2023-09-19 CN claimed
CN-114437103-B Method for synthesizing chiral tetrahydrobenzoxepin compound through gold-catalyzed asymmetric cycloaddition reaction 山东大学 2023-01-06 CN claimed
CN-114437103-A Method for synthesizing chiral tetrahydrobenzoxepin compound through gold-catalyzed asymmetric cycloaddition reaction 山东大学 2022-05-06 CN claimed
CN-107935981-B 3, 4-dihydro-1-benzoxepin derivatives, preparation method and application thereof 中国科学院上海药物研究所 2020-10-09 CN claimed
CN-110770211-A α unsaturated amide compound 协和麒麟株式会社 2020-02-07 CN claimed
US-20080119496-A1 7-Substituted Purine Derivatives for Immunosuppression PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-05-22 US claimed
WO-2008060301-A1 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA , LLC (US) 2008-05-22 WO claimed
EP-1874772-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2008-01-09 EP claimed
US-20070021443-A1 Purine and imidazopyridine derivatives for immunosuppression WYETH LLC 2007-01-25 US claimed
WO-2006108103-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2006-10-12 WO claimed
US-5194442-A 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical products based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-16 US claimed
EP-0507637-A2 Use of benzobicyclic carboxamides for the manufacture of a medicament for use as analgesic Erbamont Inc. (US) 1992-10-07 EP claimed
EP-0493041-A2 Use of benzobicyclic carboxamides for the treatment of anxiety and migraine ERBAMONT, INC. (US) 1992-07-01 EP claimed
US-5122528-A N-(1-azabicyclo(2.2.2)octyl) or N-((8-phenmethyl)-8-azabicyclo (3.2.1)octyl) benzofuryl, chromenyl or 1-benzoxepinyl carboxamides ERBAMONT, INC. (US) 1992-06-16 US claimed
EP-0360131-A1 2,3,4,5-Tetrahydro-1-benzoxepines, method for their preparation, their use and pharmaceutical compositions based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1990-03-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119496-A1 7-Substituted Purine Derivatives for Immunosuppression P2RX7, P2RX5, P2RY1 TSHR 4306/4885ITGB2 4028/4885ICAM1 2404/4885
US-20070021443-A1 Purine and imidazopyridine derivatives for immunosuppression TPMT, P2RY4, P2RY1 TSHR 3899/4885ITGB2 4154/4885ICAM1 1100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.